| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 24033 |
| Drug | Omaveloxolone |
| Brand | Skyclarys® |
| Indication | For the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older |
| Assessment Process | |
| Rapid review commissioned | 02/08/2024 |
| Rapid review completed | 29/08/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of omaveloxolone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 25/09/2024 |
| Pre-submission consultation with Applicant | 04/02/2025 |
